{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:10:05Z","timestamp":1793045405741,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T00:00:00Z","timestamp":1643500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"The Australian Rheumatology Association Database"},{"name":"Australian Rheumatology Association"},{"DOI":"10.13039\/501100000948","name":"Pfizer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000948","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AbbVie Pty Ltd"},{"name":"Eli Lilly Australia Pty Ltd Sanofi Australia"},{"name":"Celgene Australian & NZ, Bristol Myers Squibb Australia Pty Ltd"},{"DOI":"10.13039\/100019213","name":"Amgen Australia Pty Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019213","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Australian National Health and Medical Research Council"},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["384330"],"award-info":[{"award-number":["384330"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cabrini Health, Monash University, Royal North Shore Hospital"},{"name":"Australian Rheumatology Association"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study was to describe treatment patterns in RA, including the frequency and reasons for switching or stopping biologic and targeted synthetic DMARDs (b\/tsDMARDs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The reasons for switching or stopping b\/tsDMARDs were extracted from the Australian Rheumatology Association Database (ARAD) from 2003 to 2018 for RA participants. Switching patterns for each b\/tsDMARD and time on first-, second- and third-line b\/tsDMARDs were evaluated using Sankey diagrams and survival methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2839 participants were included in the analysis. The first-line b\/tsDMARDs were etanercept (n\u2009=\u20091414), adalimumab (n\u2009=\u20091024), infliximab (n\u2009=\u2009155), golimumab (n\u2009=\u200998), abatacept (n\u2009=\u200966), certolizumab (n\u2009=\u200938), tocilizumab (n\u2009=\u200921) and tofacitinib (n\u2009=\u200923). Of those starting first-, second- and third-line biologic therapy, 24.0%, 31.8% and 24.4% switched to another b\/tsDMARD within 12\u2009months, respectively. Inefficacy or adverse effects were the most common reasons for stopping therapy, irrespective of line of treatment. Compared with first-line etanercept, participants were more likely to stop adalimumab [Hazard ratio (HR) 1.16, 95% CI: 1.04, 1.29] and infliximab (HR 1.77, 95% CI: 1.46, 2.16). No differences were seen for other b\/tsDMARDs. For second-line therapies compared with etanercept, the risk of stopping was lower for tocilizumab (HR 0.41, 95% CI: 0.25, 0.70), rituximab (HR 0.51, 95% CI: 0.30, 0.85) and tofacitinib (HR 0.29, 95% CI: 0.15, 0.57). Participants taking rituximab, tocilizumab and tofacitinib were also less likely to stop third-line therapy in comparison with participants taking etanercept.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Switching between b\/tsDMARDs was common among ARAD participants with RA, most commonly due to inefficacy or adverse effects. Durability of exposure and reasons for switching varied between b\/tsDMARDs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keac048","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T07:17:16Z","timestamp":1643095036000},"page":"3939-3951","source":"Crossref","is-referenced-by-count":19,"title":["Patterns of biologic and targeted-synthetic disease-modifying antirheumatic drug use in rheumatoid arthritis in Australia"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7349-9514","authenticated-orcid":false,"given":"Ashley","family":"Fletcher","sequence":"first","affiliation":[{"name":"Monash\u2013Cabrini Department of Musculoskeletal Health and Clinical Epidemiology, Cabrini Health"},{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University , Melbourne, VIC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Lassere","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, St George Hospital"},{"name":"Department of Medicine, School of Population Health, University of New South Wales"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyn","family":"March","sequence":"additional","affiliation":[{"name":"Florance and Cope Professorial Department of Rheumatology, Royal North Shore Hospital"},{"name":"Department of Rheumatology, Institute of Bone and Joint Research at Kolling Institute, University of Sydney , Sydney, NSW"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The Queen Elizabeth and Royal Adelaide Hospitals"},{"name":"Department of Rheumatology, Discipline of Medicine, University of Adelaide , Adelaide, SA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Barrett","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Redcliffe Hospital , Redcliffe"},{"name":"Department of Medicine, School of Medicine, University of Queensland , Brisbane, QLD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme","family":"Carroll","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fiona Stanley Hospital , Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachelle","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Monash\u2013Cabrini Department of Musculoskeletal Health and Clinical Epidemiology, Cabrini Health"},{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University , Melbourne, VIC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,30]]},"reference":[{"key":"2022100812084330000_keac048-B1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res"},{"key":"2022100812084330000_keac048-B2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5694\/mja15.00716","article-title":"Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia","volume":"204","author":"Hopkins","year":"2016","journal-title":"Med J Aust"},{"key":"2022100812084330000_keac048-B3","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/ard.2007.069872","article-title":"Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue","volume":"66","author":"van Vollenhoven","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2022100812084330000_keac048-B4","first-page":"926","article-title":"High rates of stopping or switching biological medications in veterans with rheumatoid arthritis","volume":"27","author":"Oei","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"2022100812084330000_keac048-B5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/14397595.2018.1447264","article-title":"Comparing the effectiveness of biological disease-modifying antirheumatic drugs using real-world data","volume":"29","author":"Takabayashi","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2022100812084330000_keac048-B6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40744-017-0078-y","article-title":"Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the Corrona RA Registry","volume":"4","author":"Strand","year":"2017","journal-title":"Rheumatol Ther"},{"key":"2022100812084330000_keac048-B7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13075-019-1880-4","article-title":"Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis\u2014the ANSWER cohort study","volume":"21","author":"Ebina","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022100812084330000_keac048-B8","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","article-title":"Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"77","author":"Kearsley-Fleet","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022100812084330000_keac048-B9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/rheumatology\/key338","article-title":"Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry","volume":"58","author":"Olsen","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2022100812084330000_keac048-B10","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10067-017-3584-y","article-title":"Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry","volume":"36","author":"Park","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2022100812084330000_keac048-B11","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1007\/s12325-017-0578-8","article-title":"Treatment persistence and clinical outcomes of tumor necrosis factor inhibitor cycling or switching to a new mechanism of action therapy: real-world observational study of rheumatoid arthritis patients in the United States with prior tumor necrosis factor inhibitor therapy","volume":"34","author":"Wei","year":"2017","journal-title":"Adv Ther"},{"key":"2022100812084330000_keac048-B12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3111\/13696998.2014.893241","article-title":"Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting","volume":"17","author":"Meissner","year":"2014","journal-title":"J Med Econ"},{"key":"2022100812084330000_keac048-B13","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/acr.22055","article-title":"Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program","volume":"65","author":"Zhang","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022100812084330000_keac048-B14","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1080\/03007995.2021.1981278","article-title":"Treatment patterns and sequencing in patients with rheumatic diseases: a retrospective claims data analysis","volume":"37","author":"Gauthier","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"2022100812084330000_keac048-B15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/CEOR.S108730","article-title":"Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy","volume":"9","author":"Degli Esposti","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"2022100812084330000_keac048-B16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/1471-2474-12-204","article-title":"Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study","volume":"12","author":"Ogale","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"key":"2022100812084330000_keac048-B17","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.clinthera.2016.03.022","article-title":"Treatment patterns, direct cost of biologics, and direct medical costs for rheumatoid arthritis patients: a real-world analysis of nationwide Japanese claims data","volume":"38","author":"Sugiyama","year":"2016","journal-title":"Clin Ther"},{"key":"2022100812084330000_keac048-B18","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.clinthera.2015.04.012","article-title":"Impact of switching from an initial tumor necrosis factor inhibitor on health care resource utilization and costs among patients with rheumatoid arthritis","volume":"37","author":"Baser","year":"2015","journal-title":"Clin Ther"},{"key":"2022100812084330000_keac048-B19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ard.2007.070714","article-title":"Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden","volume":"67","author":"Soderlin","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2022100812084330000_keac048-B20","first-page":"182","article-title":"The thermal efficiency of steam-engines","volume":"125","author":"Sankey","year":"1896","journal-title":"Min Proc Inst Civil Eng"},{"key":"2022100812084330000_keac048-B21","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s00268-019-05267-6","article-title":"Development of a visual analytics tool for polytrauma patients: proof of concept for a new assessment tool using a multiple layer Sankey diagram in a single-center database","volume":"44","author":"Mica","year":"2020","journal-title":"World J Surg"},{"key":"2022100812084330000_keac048-B22","doi-asserted-by":"crossref","first-page":"20170063","DOI":"10.1515\/jib-2017-0063","article-title":"BioSankey: visualization of microbial communities over time","volume":"15","author":"Platzer","year":"2018","journal-title":"J Integr Bioinform"},{"key":"2022100812084330000_keac048-B23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12879-019-3732-x","article-title":"Consecutive antibiotic use in the outpatient setting: an extensive, longitudinal descriptive analysis of antibiotic dispensing data in the Netherlands","volume":"19","author":"de Jong","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2022100812084330000_keac048-B24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1445-5994.2007.01431.x","article-title":"Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database","volume":"37","author":"Buchbinder","year":"2007","journal-title":"Intern Med J"},{"key":"2022100812084330000_keac048-B25","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"2022100812084330000_keac048-B26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1023\/A:1008815005736","article-title":"The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life","volume":"8","author":"Hawthorne","year":"1999","journal-title":"Qual Life Res"},{"key":"2022100812084330000_keac048-B27","volume-title":"SF-36 physical and mental health summary scales: a user\u2019s manual","author":"Ware","year":"1994"},{"key":"2022100812084330000_keac048-B28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"2022100812084330000_keac048-B29","article-title":"Australian Rheumatoid Arthritis (RA) biologic treatment pathways: an Australian Rheumatology Association Database (ARAD) analysis","volume":"71(Suppl 10","author":"Fletcher","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2022100812084330000_keac048-B30","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","article-title":"Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings","volume":"29","author":"Bonafede","year":"2012","journal-title":"Adv Ther"},{"key":"2022100812084330000_keac048-B31","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3111\/13696998.2016.1142448","article-title":"Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system","volume":"19","author":"Rashid","year":"2016","journal-title":"J Med Econ"},{"key":"2022100812084330000_keac048-B32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s40744-014-0006-3","article-title":"Comparison of biologic disease-modifying antirheumatic drug therapy persistence between biologics among rheumatoid arthritis patients switching from another biologic","volume":"2","author":"Johnston","year":"2015","journal-title":"Rheumatol Ther"},{"key":"2022100812084330000_keac048-B33","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/03007995.2020.1754186","article-title":"Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies","volume":"36","author":"Walsh","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"2022100812084330000_keac048-B34","doi-asserted-by":"crossref","first-page":"569","DOI":"10.5114\/aoms.2016.58924","article-title":"Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009\u20132014","volume":"14","author":"T\u0142ustochowicz","year":"2018","journal-title":"Arch Med Sci"},{"key":"2022100812084330000_keac048-B35","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1080\/14397595.2018.1537556","article-title":"Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan","volume":"29","author":"Kondo","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2022100812084330000_keac048-B36","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s10067-016-3528-y","article-title":"Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry","volume":"36","author":"Monti","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2022100812084330000_keac048-B37","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.3899\/jrheum.190535","article-title":"Reasons for biologic and targeted synthetic disease-modifying antirheumatic drug cessation and persistence of second-line treatment in a rheumatoid arthritis dataset","volume":"47","author":"Youssef","year":"2020","journal-title":"J Rheumatol"},{"key":"2022100812084330000_keac048-B38","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13075-019-1917-8","article-title":"Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata(R) clinical database and registry","volume":"21","author":"Choquette","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2022100812084330000_keac048-B39","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.semarthrit.2021.06.002","article-title":"Association of first, second, and third-line bDMARDs and tsDMARD with drug survival among seropositive rheumatoid arthritis patients: cohort study in a real world setting","volume":"51","author":"Choi","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2022100812084330000_keac048-B40","doi-asserted-by":"crossref","first-page":"l67","DOI":"10.1136\/bmj.l67","article-title":"Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study","volume":"364","author":"Gottenberg","year":"2019","journal-title":"BMJ"},{"key":"2022100812084330000_keac048-B41","doi-asserted-by":"crossref","first-page":"e0216624","DOI":"10.1371\/journal.pone.0216624","article-title":"Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study","volume":"14","author":"Ebina","year":"2019","journal-title":"PLoS One"},{"key":"2022100812084330000_keac048-B42","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2147\/CEOR.S115706","article-title":"Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication","volume":"8","author":"Bonafede","year":"2016","journal-title":"Clinicoecon Outcomes Res"},{"key":"2022100812084330000_keac048-B43","author":"Lynch","year":"2021"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac048\/42752227\/keac048.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/10\/3939\/46382949\/keac048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/10\/3939\/46382949\/keac048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T08:11:40Z","timestamp":1665216700000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/10\/3939\/6517494"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,30]]},"references-count":43,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,1,30]]},"published-print":{"date-parts":[[2022,10,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac048","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,1,30]]}}}